Table 4: Proliferative indices of Libya, Nigeria, and Finland in whole patient materials and in subgroups.

Libya   (130)Finland°   (364)Nigeria*   (300)  value
Libya  versus  FinlandLibya
versus Nigeria

SMIWhole  material32.1 (21.0)13.8 (17.8)42.6 (27.5)<0.0001<0.0001
MAI27.3 (18.5)10.7 (16.5)30.5 (25.1)<0.00010.192

SMI
LN+
34.8  (21.8)   17.8  (19.3)   45.4  (27.6) <0.00010.001
LN−21.5  (13.0)   11.6  (16.5)   32.6  (25.1) 0.0030.032
Postmenopause37.7  (25.7)   11.2  (13.4)   44.9  (26.6) <0.00010.134
Premenopause28.5  (16.6)   19.6  (29.0)   41.9  (27.8) 0.014<0.0001
Grade 114.9  (9.2)   NA11.8  (11.4) NA0.427
Grade 232.1  (19.3)   NA31.7  (16.5) NA0.880
Grade 335.4  (23.3)  NA61.9  (24.5) NA<0.0001
Stage 115.7 (9.3)   NA32.6  (25.1) NA0.108
Stage 225.0  (14.5)   NA41.9  (28.3) NA<0.0001
Stage 336.1  (22.2)   NA48.9  (28.8) NA0.003
Stage 441.3  (21.0)   NA44.3  (24.4) NA0.650

MAILN+
29.0  (17.9)   13.4  (17.4)   32.7  (25.6) <0.00010.184
LN−20.6  (19.7)   9.2  (15.8)   22.6  (21.2) 0.0010.675
Postmenopause32.7 (19.8)   8.8  (11.9)   33.8  (24.9) <0.00010.793
Premenopause23.9  (17.0)   14.9  (23.2)   29.4  (22.1) 0.0040.044
Grade 112.8  (9.6)   NA4.2 (3.8) NA<0.0001
Grade 225.4  (17.1)   NA16.8  (10.1) NA<0.0001
Grade 332.7  (20.0)   NA50.9  (21.9) NA<0.0001
Stage 115.7 (9.3)   NA22.6  (21.2) NA0.434
Stage 225.0  (14.5)  NA28.3 (24.4) NA0.416
Stage 336.1  (22.2)   NA36.6 (26.8) NA0.901
Stage 441.3  (21.0) NA31.9 (24.7) NA0.162

Data on Nigeria and Finland are basically the same as those published in the study of *Ikpatt et al. [6, 7] and °Kronqvist et al. [9]. Significance is estimated by one-way ANOVA test.